A5026525918- Computational Drug Discovery Methods
- Cardiac electrophysiology and arrhythmias
- Receptor Mechanisms and Signaling
- Cancer Immunotherapy and Biomarkers
- DNA Repair Mechanisms
- Cancer therapeutics and mechanisms
- Immune Cell Function and Interaction
- Pharmacogenetics and Drug Metabolism
- Protein Structure and Dynamics
- DNA and Nucleic Acid Chemistry
- Ion channel regulation and function
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Microtubule and mitosis dynamics
- Toxic Organic Pollutants Impact
- ATP Synthase and ATPases Research
- HIV/AIDS drug development and treatment
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- vaccines and immunoinformatics approaches
- Pancreatic function and diabetes
- Regulation of Appetite and Obesity
- Hepatitis C virus research
- Growth Hormone and Insulin-like Growth Factors
- Mass Spectrometry Techniques and Applications
University of Alberta
2016-2025
Technical University of Munich
2022
Cairo University
2006-2020
Alberta Hospital Edmonton
2020
Pharmaceutical Biotechnology (Czechia)
2017
Institute of Virology of the Slovak Academy of Sciences
2016-2017
Fayoum University
2006-2016
Alberta Biodiversity Monitoring Institute
2015
Nankai University
2014
Hôpital Edouard Herriot
2013
SGLT2 (sodium/glucose cotransporter 2) inhibitors exert robust cardioprotective effects against heart failure in patients with diabetes, and there is intense interest to identify the underlying molecular mechanisms that afford this protection. Because induction of late component cardiac sodium channel current (late-
Synthetic and natural peptides that act as nonselective melanocortin receptor agonists have been found to be anorexigenic stimulate erectile activity. We report the design development of 1, a potent, selective (1184-fold vs MC3R, 350-fold MC5R), small-molecule agonist MC4 receptor. Pharmacological testing confirms food intake lowering effects MC4R agonism suggests another role for in stimulation
Abstract Blockade of the programmed cell death 1 (PD-1)/programmed death-ligand (PD-L1) interaction has emerged as a powerful strategy in cancer immunotherapy. Recently, there have been enormous efforts to develop potent PD-1/PD-L1 inhibitors. In particular, Bristol-Myers Squibb (BMS) and Aurigene Discovery Technologies individually disclosed several promising inhibitors, whose detailed experimental data are not publicly disclosed. this work, we report rigorous systematic vitro...
Influenza is a major cause of morbidity and mortality in immunosuppressed persons, vaccination often confers insufficient protection. IL-28B, member the interferon (IFN)-λ family, has variable expression due to single nucleotide polymorphisms (SNPs). While type-I IFNs are well known modulate adaptive immunity, impact IL-28B on B- T-cell vaccine responses unclear. Here we demonstrate that presence TG/GG genotype (rs8099917, minor-allele) was associated with increased seroconversion following...
The benefit of cancer chemotherapy based on alkylating agents is limited because the action DNA repair enzymes, which mitigate damage induced by these agents. interaction between proteins ERCC1 and XPF involves two major components nucleotide excision pathway. Here, novel inhibitors this were identified virtual screening available structures with use National Cancer Institute diversity set a panel DrugBank small molecules. Subsequently, experimental validation in silico was undertaken. Top...
The cytoskeleton is essential to cell morphology, cargo trafficking, and division. As the neuronal extremely complex, it no wonder that a startling number of neurodegenerative disorders (including but not limited Alzheimer's disease, Parkinson's disease Huntington's disease) share common feature dysfunctional cytoskeleton. Recently, concern has been raised about possible link between anesthesia, post-operative cognitive dysfunction, exacerbation disorders. Experimental investigations suggest...
Feedback mechanisms between interferons α and λ (IFNs) may be affected by single nucleotide polymorphisms (SNP) in interleukin 28B (IL-28B; IFN-λ3) promoter region influence cytomegalovirus (CMV) replication.We associated IL-28B SNPs with the risk of CMV replication after transplantation. Next, we examined effect genotypes on IL-28B, IFN-stimulated gene (ISG) expression, human foreskin fibroblast (HFF) peripheral blood mononuclear cells (PBMCs).Transplant recipients an SNP (rs8099917) had...
In the field of drug discovery, there is a substantial challenge in seeking out chemical structures that possess desirable pharmacological, toxicological, and pharmacokinetic properties. Complications arise when drugs interfere with functioning cardiac ion channels, leading to serious cardiovascular consequences. The discontinuation removal numerous approved from market or at late development stages pipeline due such inhibitory effects further highlight urgency addressing this issue....
Background Nucleotide excision repair (NER) removes many types of DNA lesions including those induced by UV radiation and platinum-based therapy. Resistance to therapy correlates with high expression ERCC1, a major element the NER machinery. The interaction between ERCC1 XPA is essential for successful function. Therefore, one way regulate inhibiting activity XPA. Methodology/Principal Findings Here we continued our earlier efforts aimed at identification characterization novel inhibitors...
Beta-Caryophyllene (BCP), a naturally occurring sesquiterpene abundantly found in cloves, hops, and cannabis, is the active candidate of relatively new group vascular-inhibiting compounds that aim to block existing tumor blood vessels. Previously, we have reported anti-cancer properties BCP by utilizing series in-vitro anti-tumor-related assays using human colorectal carcinoma cells. The present study aimed investigate effects on in-vitro, ex-vivo, in-vivo models anti-angiogenic evaluate its...
Many direct-acting antiviral agents (DAAs) that selectively block hepatitis C virus (HCV) replication are currently under development. Among these is Daclatasvir, a first-in-class inhibitor targeting the NS5A viral protein. Although Daclatasvir most potent HCV molecule yet developed, its binding location and mode of remain unknown. The drug exhibits low barrier to resistance mutations, particularly in genotype 1 viruses, but efficacy against other genotypes unclear. Using state-of-the-art...